bioAffinity Technologies(BIAF) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) For the fiscal year ended December 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-41463 22211 W Interstate 10 Suite 1206 San Antonio, Texas 78257 (Address of Principal Executive Offices) (Zip Code) | --- | --- | --- | |-------------------------------------------------------|---------------------|--------------------------------------------------- ...